Notice: This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends OBLN vs. SGHT, PDEX, BWAY, NVRO, QIPT, SRTS, TLSI, TELA, GUTS, and MGRMShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Sight Sciences (SGHT), Pro-Dex (PDEX), BrainsWay (BWAY), Nevro (NVRO), Quipt Home Medical (QIPT), Sensus Healthcare (SRTS), TriSalus Life Sciences (TLSI), TELA Bio (TELA), Fractyl Health (GUTS), and Monogram Orthopaedics (MGRM). These companies are all part of the "medical" sector. Obalon Therapeutics vs. Sight Sciences Pro-Dex BrainsWay Nevro Quipt Home Medical Sensus Healthcare TriSalus Life Sciences TELA Bio Fractyl Health Monogram Orthopaedics Obalon Therapeutics (NASDAQ:OBLN) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the MarketBeat Community favor OBLN or SGHT? Obalon Therapeutics received 229 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 48.24% of users gave Obalon Therapeutics an outperform vote while only 29.82% of users gave Sight Sciences an outperform vote. CompanyUnderperformOutperformObalon TherapeuticsOutperform Votes24648.24% Underperform Votes26451.76% Sight SciencesOutperform Votes1729.82% Underperform Votes4070.18% Which has better valuation & earnings, OBLN or SGHT? Obalon Therapeutics has higher earnings, but lower revenue than Sight Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObalon Therapeutics$1.59M27.61-$12.33MN/AN/ASight Sciences$79.54M2.28-$55.55M-$1.02-3.50 Do analysts rate OBLN or SGHT? Sight Sciences has a consensus price target of $5.12, indicating a potential upside of 43.42%. Given Sight Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Sight Sciences is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sight Sciences 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is OBLN or SGHT more profitable? Sight Sciences has a net margin of -63.30% compared to Obalon Therapeutics' net margin of -776.76%. Sight Sciences' return on equity of -47.28% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Obalon Therapeutics-776.76% -161.38% -83.58% Sight Sciences -63.30%-47.28%-32.72% Does the media prefer OBLN or SGHT? In the previous week, Sight Sciences had 2 more articles in the media than Obalon Therapeutics. MarketBeat recorded 2 mentions for Sight Sciences and 0 mentions for Obalon Therapeutics. Sight Sciences' average media sentiment score of 0.40 beat Obalon Therapeutics' score of 0.00 indicating that Sight Sciences is being referred to more favorably in the news media. Company Overall Sentiment Obalon Therapeutics Neutral Sight Sciences Neutral Do institutionals & insiders believe in OBLN or SGHT? 18.6% of Obalon Therapeutics shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 8.1% of Obalon Therapeutics shares are owned by insiders. Comparatively, 28.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, OBLN or SGHT? Obalon Therapeutics has a beta of -1.23, indicating that its share price is 223% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.58, indicating that its share price is 158% more volatile than the S&P 500. SummarySight Sciences beats Obalon Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.90M$4.34B$5.14B$9.08BDividend YieldN/A44.57%5.09%4.23%P/E Ratio-3.2425.3790.1317.18Price / Sales27.6145.881,116.34117.09Price / CashN/A43.4043.1037.85Price / Book7.307.094.784.78Net Income-$12.33M$13.64M$120.31M$225.60M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$4.38-2.0%N/A+1,331.4%$43.90M$1.59M-3.242Analyst ForecastGap DownSGHTSight Sciences3.3907 of 5 stars$3.68+2.8%$5.12+39.1%+13.3%$186.80M$81.06M-3.51210News CoveragePDEXPro-Dex1.6372 of 5 stars$48.80-1.3%$52.00+6.6%+188.2%$159.09M$53.84M32.10140BWAYBrainsWay4.0331 of 5 stars$9.53+1.2%$13.17+38.2%+33.3%$158.94M$38.63M95.20120NVRONevro2.1387 of 5 stars$4.23+3.9%$8.05+90.3%-82.2%$158.50M$425.17M-2.231,215Analyst ForecastQIPTQuipt Home Medical2.5482 of 5 stars$3.09+2.7%$6.25+102.3%-51.7%$133.15M$221.74M-27.361,200Earnings ReportAnalyst RevisionNews CoveragePositive NewsGap UpSRTSSensus Healthcare3.7704 of 5 stars$7.98-2.2%$12.50+56.6%+177.3%$130.79M$24.41M14.3240TLSITriSalus Life Sciences4.02 of 5 stars$3.90-0.3%$12.08+209.8%-49.7%$118.92M$26.89M-1.57106Analyst ForecastInsider TradeNews CoveragePositive NewsGap UpTELATELA Bio2.9878 of 5 stars$2.84+2.5%$9.25+225.7%-53.6%$111.87M$58.45M-1.64120GUTSFractyl Health0.8783 of 5 stars$2.11+3.4%$22.00+942.7%N/A$101.49M$120,000.00-0.17102MGRMMonogram Orthopaedics3.2283 of 5 stars$2.78+4.5%$4.00+43.9%-23.1%$95.39M$364,999.00-5.6628 Related Companies and Tools Related Companies SGHT Competitors PDEX Competitors BWAY Competitors NVRO Competitors QIPT Competitors SRTS Competitors TLSI Competitors TELA Competitors GUTS Competitors MGRM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OBLN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OBLN Stock Alerts